DeepCure, a pioneer in AI-powered small molecule drug discovery, has closed a $24.6 million Series A-1 financing round led by IAG Capital Partners. This brings the total funding raised by DeepCure to over $72 million since its inception.
DeepCure’s innovative platform combines generative AI with physics-based engines to discover novel small-molecule therapies for complex targets. It pinpoints potential interaction sites on proteins and designs synthesizable molecules with optimal properties. Additionally, DeepCure has developed an automated chemistry synthesis platform to enhance the tested molecules’ speed, quantity, and diversity.
“DeepCure has achieved technical breakthroughs in AI and chemistry synthesis automation that overcome critical barriers for small molecule discovery,” said Dr. Ehsan Jabbarzadeh, Venture Partner at IAG.
The Series A-1 proceeds will accelerate DeepCure’s technology development and advance its immunology and inflammation pipeline toward clinical trials.
IAG Capital Partners’ investment aligns with its commitment to supporting early-stage companies with transformative technologies. “These breakthroughs are pivotal to drugging a huge number of intractable targets that are known to have a central role in disease biology,” said Alex Kash, Associate at IAG.
DeepCure’s mission is to leverage its AI and automation capabilities to transform drug discovery and bring novel treatments to patients suffering from immunology-related and inflammatory diseases.
Source link: http://www.businesswire.com/news/home/20240411173088/en/DeepCure-Closes-24M-Funding-Round-Led-by-IAG-Capital-Partners
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
